Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine

Surakameth Mahasirimongkol[1*], Athiwat Khunphon[1], Oraya Kwangsukstid[3]
Sompong Sapsutthipas[2],Minkwan Wichaidit[3],Archawin Rojanawiwat[5]
Nuanjun Wichuckchinda[1],Wiroj Puangtubtim[1],Warangluk Pimpapai[1]
Sakulrat Soonthorncharttrawat[1], Asawin Wanitchang[6]
Anan Jongkaewwattana[6],Kanjana Srisutthisamphan[6] ,Daraka Phainupong[3]
Penpitcha Thawong[1], Pundharika Piboonsiri[1],Warittha Sawaengdee[1]
Thitiporn Somporn[2], Kanokphon Ritthitham[2],Supaporn Chumpol[2]
Nadthanan Pinyosukhee[1], Rattanawadee Wichajarn[1]
Panadda Dhepaksorn[1],Sopon Iamsiritahworn[4], Supaporn Phumiamorn[2]

Affiliations:
[1]Medical Life Sciences Institute, Department of Medical Sciences, Nonthaburi, Thailand.
[2]Institute of Biological Products, Department of Medical Sciences Nonthaburi, Thailand.
[3]Institute of Dermatology, Department of Medical Service, Nonthaburi, Thailand
[4] Division epidemiology, Department of disease control, Nonthaburi, Thailand

[5] National Institute of Health, Nonthaburi, Thailand

[6] Virology and Cell technology Research Team, National Center for Genetic Engineering and Biotechnology(BIOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani, Thailand

Corresponding Author: Surakameth Mahasirimongkol, MD, Ph.D.

Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health

88/7 Tivanond Road ,Nonthaburi 11000, Thailand

Tel: (+66) 2951000 ,0-2589-9580-8; Fax: (+66) 2-591-1707

E-mail: Surakameth.m@dmsc.mail.go.th

Abstract

Background: Responding to SARS-CoV-2 Delta variants escaped the vaccine-induced immunity and waning immunity from the inactivated whole virus vaccine, Thailand recently proposed a heterologous inactivated whole virus vaccine (CoronaVac) viral vector vaccine (ChAdOx1 nCoV-19) prime-boost vaccine regimen(I/V). This study aims to evaluate the immunogenicity and adverse events of this regimen by comparison with homologous CoronaVac, ChAdOx1 nCoV-19, and convalescent serum.

Method: Immunogenicity was evaluated by the level of IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (S1 subunit) (anti-S RBD). At 2 weeks following the second dosage, a selection of random samples was tested for plaque reduction neutralisation (PRNT) and Pseudotype-Based Microneutralization test (PVNT) against SARS-CoV-2 variants of concern (VOCs). The safety profile of heterologous CoronaVac-ChAdOx1 nCoV-19 prime-boost vaccine regimen was described by interviewing at the 1-month visit.

Result: Between April to August 2021,426 participants were included in the study, with 155 obtaining CoronaVac-ChAdOx1 nCoV-19(I/V),32 obtaining

homologous CoronaVac(I/I),47 obtaining homologous ChAdOx1 nCoV-19(V/V),169 with history covid-19 infection. Geometric mean titers (GMTs) of anti-S RBD level in the I/V group compare 2wks and 4 wks (873.9 vs 639,p=0.00114).At 4 wks, GMTs of anti-S RBD level in I/V group was 639, 95% CI 63-726,and natural infection group 177.3, 95% CI 42-221, and V/V group 211.1, 95% CI 77-152 ,and I/I group 108.2 ,95% CI 77-152 ; all p<0.001).At 2 wks, The GMTs of 50%PRNT of 19 sampling from the I/V group is 434.5, 95% CI 326-579, against wild type and 80.4, 95% CI 56-115, against alpha and 67.4, 95% CI 48-95, against delta and 19.8, 95% CI 14-30, against beta; all p<0.001. At 2 wks, The GMTs of 50%PVNT of 15 sampling from the I/V group is 597.8, 95% CI 368-970, against wild type and 163.9, 95% CI 89-301, against alpha and 157.7, 95% CI 66-378, against delta. The AEs in the I/V schedule were well tolerated and generally unremarkable.

Conclusion: The I/V vaccination is a mixed regimen that induced higher immunogenicity and shall be considered for responding to Delta Variants when only inactivated whole virus vaccine and viral vector vaccine was available.

Background

In lower and middle-income countries, where the access to the COVID-19 vaccine is limited in 2021, the estimated total COVID19 vaccine in 2021 is 4 billion doses while the demand is around 8 billion doses. Lower and middle-income countries relied on the COVID-19 vaccine such as the inactivated whole virus vaccine, CoronaVac[1] (Sinovac Biotech, Beijing, China), and viral vector vaccine such as ChAdOx1 nCOV-19 vaccine[2].

The heterologous prime-boost vaccination has been reported to be induced higher immunogenicity for various vaccine[3] and routinely practice in the annual vaccination program such as influenza, or in the vaccination program, where vaccination of different manufacturing platforms is considered replaceable. While only one covid vaccine was designed based on heterologous rAd26 and rAd5 vector-based COVID-19 vaccination, which enables a high level of immunogenicity[4].Most of the vaccines were not utilized the heterologous vaccination concept because most manufacturers did not develop the vaccine from two different vaccine delivery platforms or manufacturing platforms. It is a generally higher cost for manufacturing vaccines with two manufacturing platforms. The outbreaks of Delta variants from the beginning of 2021 in India are devastating with estimates of 10 times higher number of deaths than the

reported deaths due to its higher transmissibility, more severe and vaccine escape capability[5]. Based on these characteristics, the Delta variant was recognized as the variants of concerns (VOCs) by Public Health England, US Center for Disease Control, and World Health Organization (WHO). WHO issued global notices of Delta variant as the dominant variants and notification of the vaccination program to accelerate the implementation of any vaccine that is readily accessible. The outbreaks of the Delta variant in Indonesia occurred in the middle of 2021[6]. In July 2021, the Royal Society of Physicians in Indonesia reported the highest mortality rates from COVID19 in health care workers who were fully vaccinated with CoronaVac, this report[6] prompted global concerns about the efficacy of inactivated viral vaccine against the Delta variants after several months post-vaccination.In some countries where the inactivated viral vaccine was used at the beginning of 2021, such as Bahrain, China, United Arab Emirates, and Egypt, the booster dose (third dose) by mRNA vaccine were offered to elderly and high-risk populations in the middle of 2021[7] The immunogenicity study of inactivated whole virus vaccine in Thailand suggested that inactivated virus vaccine with Wuhan's variant S protein provided low immunogenicity against the alpha and Delta variant [8]. The Delta variant in Thailand was first detected in May 2021, from the construction workers site in the Laksi district of Bangkok, where workers from Myanmar and Cambodia worked with Thai nationals. Within 3 months duration, and multiple outbreaks of the Delta variant, it took over the Alpha variant which predominated in

132 Bangkok from April to May, and became the dominant variants of COVID19 in
133 Thailand in the first week of August 2021. Like other countries in Southeast
134 Asia, Thailand began the COVID-19 vaccination program with CoronaVac and
135 ChAdOx1 nCOV-19, viral vector vaccine from AstraZeneca, mainly due to the
136 accessibility of the inactivated viral vaccine from China. While the vaccination
137 program was implemented from March to May 2021, a group of individuals
138 who experienced vaccine-induced adverse reactions from CoronaVac was
139 offered the ChAdOx1 nCOV-19 as the only possible alternative to CoronaVac,
140 and their immunogenicity was measured and reported[9]. Based on
141 immunogenicity data in those who experienced AEs from CoronaVac, a
142 heterologous vaccine schedule, priming with inactivated SARS-CoV-2 vaccine
143 and followed with viral vector vaccine were proposed and adopted based on the
144 neutralizing antibody data from this vaccine schedule by the national
145 vaccination program on 12th July 2021. Therefore, Thailand proposed the
146 heterologous prime-boost regimen, a 21-day interval between the first dose
147 inactivated whole virus vaccine (CoronaVac) and the second dose viral vector
148 vaccine (ChAdOx1 nCoV-19 vaccine), from now we called this the "I/V"
149 regimen, the only regimen that available as the preferred schedule along with
150 the existing vaccine schedule for mitigating the mortality of COVID19
151 pandemic in Thailand. However, the immunogenicity in a larger number of
152 samples and detailed information of common reactogenicity especially the
153 adverse reaction of the second vaccination dose of ChAdOx1 nCoV-19 after

154 inactivated viral vaccine had never been reported. Here we aim to determine
155 the immunogenicity two weeks and four weeks after vaccination with the I/V
156 schedule and describe the common adverse drug reactions from this I/V
157 schedule.

158 **Method**

159 **Study design.** In this observational study, two groups of healthy individuals
160 without a known history of covid-19 infection or exposure were recruited in this
161 study. Their covid-19 infection or exposure were verified by interviewing and
162 re-checking with the national registry of COVID-19. In I/V group was divided
163 into two subgroups 1a and 1b. First, Group 1a, 30 participants, who received
164 CoronaVac were those who experienced at least an adverse event following
165 immunization and health care providers recommended that their second covid-
166 19 vaccine should be switched to ChAdOx1 nCoV-19. Within the first half of
167 2021, only ChAdOx1 nCoV-19 is available in Thailand as the alternative to the
168 inactivated viral vaccine. These patients were recruited from
169 the Bangsue central vaccination center, the largest center for COVID-19
170 vaccination in Thailand. The group 1b of participants were enrolled
171 from MOPH vaccination center vaccination site at the permanent secretary
172 office of the Ministry of Public health, those who were scheduled to receive a
173 second dose of inactivated viral vaccine were offered to switch their second
174 dose vaccination to ChAdOx1 nCoV-19. The offer is based on the

175 recommendation to I/V vaccination from the national vaccination academic
176 subcommittee. The benefit of this I/V regimen was an opportunity to achieve
177 higher immunogenicity than I/I regimens and in shorter duration intervals when
178 compared to the V/V regimen, the risk was the possibility of a higher rate of
179 adverse events than the I/I schedule.
180 The benefit and risks of second vaccination with ChAdOx1 nCoV-19 were
181 explained to participants. The ethical approval of this study was approved by
182 the ethical committee of the Department of Medical Sciences with approval
183 number; MOPH 0625/EC060. Written informed consent was obtained from all
184 participants.
185 Vaccination was performed according to the vaccination center guideline; the
186 timing and lot of vaccines were recorded in the national vaccine information
187 system called "Ministry of Public Health Vaccine Information Center (MOPH-
188 IC)".Immunogenicity analysis after the secondary vaccination at
189 the Bangsue central vaccination center (BCVC) was offered as the test-based
190 voluntarily. All participants provided written informed consent to have their
191 immunogenicity and the adverse event included in this study.-
192 All participants were invited to monitor immunogenicity at 2 weeks and 4
193 weeks after the second vaccination with ChAdOx1 nCoV-19.
194 The immunogenicity data from the fully vaccinated viral vector vaccine (V/V
195 group) were retrieved from participants at BCVC.

196 The fully vaccinated inactivated virus vaccine (I/I group) was recruited from
197 another vaccine study in DMSc.The convalescent serum from those with
198 COVID-19 Delta variant infection from Laksi district was utilized for
199 immunogenicity analysis on Natural infection in 2021 (NI group). Written
200 informed consent was acquired from these two groups of fully vaccinated
201 individuals and one group of natural infection 2021. The timing of samples
202 collected from I/I groups and V/V groups was at 4 weeks after vaccination.
203

204 **Quantification of SARS-CoV-2 anti-S RBD antibody**

205 The level of immunoglobulin class G (IgG) antibodies to the receptor-binding
206 domain (RBD) of S1 subunit spike protein of SARS-CoV-2 was measured and
207 quantified in human serum or plasma by using the ARCHITECT System
208 (Abbott, Abbott Park, Illinois, USA) chemiluminescent microparticle
209 immunoassay (CMIA) (SARS-CoV-2 IgG II Quant, Abbott Ireland, Sligo,
210 Ireland) with measuring reportable range from 6.8 Abbott Arbitrary Unit
211 (AU/mL) to 80,000.0 AU/mL (up to 40,000 AU/mL with onboard 1:2 dilution).
212 Values higher than 50 AU/mL were considered positive. Based on the evaluated
213 dilutions of the World Health Organization (WHO) International Standard
214 (NIBSC Code 20-136) for anti-SARS-CoV-2 human immunoglobulin in WHO
215 binding antibody unit (WHO BAU/mL) with the SARS-CoV-2 IgG II
216 Quant assay with Abbott internal reference calibrators, the correlation between

217 relationships of the AU/mL unit to the WHO (BAU/mL unit is at 0.142 ×
218 AU/mL) with the 0.999 correlation coefficient.

219 **Pseudotype-Based Microneutralization Assay against SARS-CoV-2**

220 Pseudotype-Based Microneutralization Assay was carried out at the viral
221 vaccine research center, National center for sciences and technology
222 (NSTDA). Pseudotyped viruses (PVs) were produced in HEK293T/17 cells.
223 HEK293T/17 producer cells were sub-cultured in 6-well plates (Thermo Fisher
224 Scientific, Waltham, MA, USA) and co-transfected at 80-90% confluence with
225 the p8.91 lentiviral packaging plasmid (500 ng), the pCSFLW firefly luciferase
226 reporter plasmid (1 µg), and the pCAGGS plasmid encoding codon-optimized
227 SARS-CoV-2 spike (1.5µg)[10]. The transfection was performed
228 using polyethylenimine (PEI). The cell supernatants were collected 72 h before
229 storage in microcentrifuge tubes at −80 °C.

230 Pseudotype-based microneutralization (pMN) assays were performed as
231 previously described[10] with some modifications. Briefly, human sera from
232 SARS-CoV-2 seropositive and seronegative were subjected to two-fold dilution
233 (starting from 1:40) in a white flat-bottom 96-well tissue culture-treated plate,
234 and 50 µL of PV containing supernatant diluted in complete DMEM to give 5 ×
235 10^5 RLU equivalent was added per well. The plate was then centrifuged at 300×
236 g for 3 min before incubation in a humidified cell-culture incubator for 1 h at 37
237 °C, 5% CO_2. Subsequently, HEK293T cells stably expressing human ACE2 and
238 TMPRSS2 (1.5 x10^4 cells/well) were mixed with the PV-serum complex before

239 incubation in a humidified cell-culture incubator for 48 h at 37 °C in 5% CO_2.
240 To measure luminescence activity, equal volumes of Bright-
241 Glo™ reagent (Promega, Madison, WI, USA) and Phosphate Buffered Saline
242 (PBS) were mixed and 25 µL added to each well; luminescence output was
243 measured using a Synergy™ HTX Multi-Mode Microplate Reader (BioTek,
244 Winooski, VT, USA) after 5 min incubation at room temperature. Analysis was
245 performed by non-linear regression after normalization to 100% and 0%
246 neutralization using GraphPad Prism Software.
247
248 **Plaque Reduction Neutralization Test (PRNT)**
249 PRNT in this study is developed and tested by the Institute of Biological
250 Products, WHO- contracted laboratory at the Department of Medical
251 Sciences. Vero cells were seeded at 2x 10^5 cells/well/ 3 ml and placed in 37°C,
252 5% CO2 incubator for 1 day. Test serum was initially diluted at 1:10, 1:40,
253 1:160, and 1:640, respectively. The SARS-CoV-2 virus was diluted in a culture
254 medium to yield 40-120 plaques/well in the virus control wells. Cell control
255 wells, convalescent patient serum, and normal human serum were also included
256 as assay controls. The neutralization was performed by mixing the equal volume
257 of diluted serum and the optimal plaque numbers of SARS CoV-2 virus at 37˚C
258 in the water bath for 1 hr. After removing the culture medium from Vero cell
259 culture plates, 200 ul of the virus-serum antibody mixture were inoculated into
260 monolayer cells and then rocked the culture plates every 15 min for 1 h. Three

261 ml of overlay semisolid medium (containing 1% of carboxymethylcellulose,
262 Sigma Aldrich, USA, with 1% of 10,000 units/ml Penicillin-10,000 ug/ml
263 Streptomycin (Sigma, USA) and 10% FBS) were replaced after removing
264 excessive viruses. All plates were incubated at 37OC, 5% CO2 for 7 days. Cells
265 were fixed with 10% (v/v) formaldehyde then stained with 0.5% crystal violet
266 in PBS. The number of plaques formed was counted in triplicate wells and the
267 percentage of plaque reduction at 50% (PRNT50) was calculated. The PRNT50
268 titer of the test sample is defined as the reciprocal of the highest test serum
269 dilution for which the virus infectivity is reduced by 50% when compared with
270 the average plaque counts of the virus control and was calculated by using a
271 four-point linear regression method. Plaque counts for all serial dilutions of
272 serum were scored to ensure that there was a dose-response.

273 **Monitoring of adverse events after vaccination**

274 Adverse events (AEs) were determined according to the SOP 43-05-17-CL-006
275 Handling and reporting of Adverse Events protocol, AEs were retrieved from
276 questionnaires and/or telephone-based interviews. The registered nurse
277 contacted all subjects, and none of them reported any serious adverse
278 effects. The rates of each adverse drug reaction were reported. The Common
279 Terminology Criteria for Adverse Events - Version 5.0 used to evaluate the
280 severity of AEs.
281

Statistical analysis

All the statistical analyses were performed using R (version 4.0.2) [11] and Rstudio (version 1.3.1093)[12]. The anti-SARS-CoV-2 RBD IgG level, $PRNT_{50}$ titer, and $PVNT_{50}$ titer were presented as geometric mean titers (GMTs) with 95 percent confidence intervals (CI).The difference of the antibody levels between vaccine groups: NI, I/I, I/V, V/V, at 4 weeks with between 2weeks and 4 weeks after having the I/V schedule were tested using the non-parametric (The Mann–Whitney U test)[13] (available within the R package rstatix). The Wilcoxon signed-rank test, a non-parametric statistical hypothesis test for paired data [13], was applied to compare the $PRNT_{50}$ titers and $PVNT_{50}$ titers among selected SARS-CoV-2 variants. The Spearman's rank correlation coefficient [11] (R function cor. test) was used to assess how well the relationship between SARS-CoV-2 variants and neutralization Assays: $PVNT_{50}$ and $PRNT_{50}$.

Results

Between April to August 2021,403 participants were included in the study, with 155 obtaining CoronaVac-ChAdOx1 nCoV-19 (I/V group),32 obtaining homologous CoronaVac (I/I group),47 obtaining homologous ChAdOx1 nCoV-19(V/V group),169 with history covid-19 infection (NI group) (figure 1,2).In I/V group,155 participants were 76(49.3%) male and 79 (50.97%) female. The

303 median age was 40 years (SD 9.4), 124 (80%) participants in 18–49 years and
304 31(20%) of participants are in 50-70 years.
305 The Demographic data between vaccination groups were described in Table 1.
306

307 **Immunogenicity profiles of I/V schedule compared with other vaccine**
308 **schedules in Thailand**

309 At 2wks visits, 149 participants were in the I/V group;6 participants missed
310 their 2 wks visit but returned for visit at 4 weeks; geometric mean titers (GMTs)
311 of anti-S RBD levels were at 873.9 BAU/mL (95% CI 768.4-993.8).

312 At 4 wks visit, 137 participants in I/V group, excluded 18 participants;
313 1 participant excluded due to HIV and low CD4 count, 2 participants infected
314 with covid 19 after 2 weeks visit and 15 participants were lost to follow up;
315 GMTs of anti-S RBD levels were at 639 BAU/ml (95% CI 63-726).
316 At 4 wks after the 3-6 weeks (mean 3.5 wks) interval between the two-dose
317 CoronaVac, 32 participants with GMTs of anti-S RBD levels were 108.2
318 BAU/mL(95% CI 77-152).
319 At 4 wks after the 8-12 weeks interval between the two-dose
320 ChAdOx1 nCoV-19, 47 participants with GMTs of anti-S RBD
321 levels were at 211.1 BAU/mL (95% CI 162-249).

322 For the natural infection group, 169 participants with documented covid 19
323 infection from Laksi district with GMTs of anti-S RBD levels were

324 177.3 BAU/ml (95% CI 42-221). Most of the natural infection groups are
325 asymptomatic individuals.
326 At 4 wks following the I/V schedule provided significantly higher GMTs of
327 anti-S RBD level when compared with I/I, V/V schedule, and natural infection
328 group($p<0.001$).
329

330 **Antibody levels at 2 weeks after second vaccination compared with 4 weeks**
331 -The antibody levels of the I/V schedule at 2 wks are significantly ($p=0.00114$)
332 (873.9 BAU/mL, 95% CI 768.4-993.8) higher than the I/V schedule at 4 wks
333 (639 BAU/mL, 95% CI 63-726). (Figure 4)
334 - The antibody levels of I/V schedule at 4 wks after second vaccination
335 is significantly ($p<0.001$) (639 BAU/mL, 95% CI 63-726) higher than the
336 V/V group (211.1 BAU/mL, 95% CI 162-249), NI group (177.3 BAU/mL, 95%
337 CI 42-221), I/I group (108.2 BAU/mL, 95% CI 77-152). (Figure 3)
338 An exceptional participant with undetectable antibody was characterized for the
339 low level of the Binding Antibody Unit at 2.4 AU/mL, due to high-risk
340 occupation from the interview, the participant was subsequently counseled for
341 the HIV screening and tested positive with an anti-HIV rapid screening test (SD
342 BIOINE HIV1/2 3.0, Standard Diagnostics, Kyonggi-Do, South Korea) and the
343 CD4 level, at 6.8 %. This patient was then referred to confirmatory diagnosis
344 and treatment of HIV. This participant was excluded from further analysis.

345 **COVID19 breakthrough infection following immunization**

346 During a telephone interview, two participants reported to the investigator that
347 they couldn't attend the 4 wks visit for blood samples collection due to their
348 COVID19 situation that they experienced during the third week after the I/V
349 schedule. These two participants in the age range 30-35 are living in the same
350 household. BAU data at 2 weeks were as followed: the first participant
351 had 380.3 BAU/ml whereas the second participant had 1,145.7 BAU/ml. The
352 two participants were confirmed with COVID19 infection by RT-PCR at a
353 private hospital, the first participant was diagnosed with COVID19 3 days
354 earlier than the second participant and both of them experienced mild
355 symptomatic covid 19 (with fever, malaise, and headache).
356 Their physician treated them with favipiravir, an antiviral agent, under a home
357 isolation scheme, followed up chest radiography was unremarkable and reported
358 no further complication.
359

360 **Neutralization antibody to variants of concern**

361 The $PRNT_{50}$ of 19 samples from the I/V schedule was analyzed and reported in
362 figure 5 and table 7. While all 19samples demonstrated the neutralizing activity
363 against the Alpha and Delta variant at > 10 IC cut-off, the neutralizing activity to
364 Beta variants was achieved in 63% of these samples. In 19 participants from the
365 I/V group were evaluated for their neutralizing antibody (Nab) by $PRNT_{50}$ for

366 4 variants of SARS-CoV-2 (Wuhan-strain or wild type, Alpha variant, Delta
367 variant, Beta variant). At 2 wks,the $PRNT_{50}$ was the highest against wild
368 type (434.5 BAU/mL, 95% CI 326-579),that significantly higher than to Alpha
369 variant (80.4 BAU/mL, 95%CI 56-115),Delta variant (67.4 BAU/mL, 95% CI 48-
370 95) and Beta variant(19.8 BAU/mL, 95%CI 14-30),respectively ($p<0.001$).

371 Moreover, their $PRNT_{50}$ had the correlation coefficient with Ab to anti-s RBD
372 level with wild type-(ρ =0.82, $p<0.001$), alpha variant
373 (ρ =0.66, p=0.0027), and Beta variant (ρ =0.074, p=0.76), delta variant
374 (ρ =0.17, p=0.48) (Figure 7).

375 In addition, all participants (n=19/19) had $PRNT_{50}$ titers ≥10
376 (Nab positivity cut-off) ≥10 (Nab positivity cut-off) against wild type, Alpha, and
377 Delta strains. Participants (n=12/19,63%) had $PRNT_{50}$ titers ≥10 against beta
378 variant (Table 9).

379

380

381 **Pseudo Neutralization antibody to variants of concern (PVNT)**

382 The $PVNT_{50}$ of 15 samples from the I/V schedule was analyzed and reported in
383 figure 6 and table 8. From the I/V group, 15 participants were evaluated for
384 their neutralizing antibody (Nab) by $PVNT_{50}$ for 3 variants of SARS-CoV-
385 2 (wild type, Alpha variant, Delta variant). Beta variant for $PVNT_{50}$ was not
386 available at the time of this study. At 2 wks, the GMTs of $PVNT_{50}$ is the highest

387 against wild type (597.8, 95% CI 368-970) that significantly ($p<0.001$)
388 greater than Alpha variant (163.9, 95% CI 89-301) and delta variant (157.7,
389 95% CI 66-378) ($p<0.001$). Furthermore, their $PVNT_{50}$ were not significantly
390 correlated with anti-s RBD level ($\rho = 0.39$, $p=0.16$), alpha variant ($\rho =0.47$,
391 $p=0.076$) and delta variant ($\rho =0.26$, $p=0.35$) (Figure 8).
392 When considering the $PVNT_{50\ titers} \geq 40$ (Nab positivity cut-off) , we
393 demonstrated that all participants (n=15/15) achieved $PVNT_{50}$ titers > 40 against
394 wild type and Alpha variant. Participants (n=13/15,86.67%) had
395 $PVNT_{50}$ titers ≥10 against beta variant (Table 9).
396 Additionally, the correlation between $PVNT_{50}$ titer with $PRNT_{50}$ titer were wild
397 type ($\rho =0.62$, $p=0.015$), alpha variant ($\rho =0.82$, $p=0.00022$), and Delta variant
398 ($\rho =0.81$, $p=0.00044$) (Figure 9).
399
400
401
402 **Adverse events following immunization**
403 **Reactogenicity to first dose CoronaVac**
404 The reactogenicity population consisted of 155 individuals in the I/V group who
405 got the second dosage of ChAdOx1 nCoV-19
406 The adverse events (AEs) to the first vaccine dose with CoronaVac in this study
407 were described separately into two groups of samples. Group 1a was 30

408 participants from Bangsue Vaccination Center (BVC), who reported a higher
409 rate of AEs from CoronaVac. Most AEs were mild and moderate symptoms
410 such as immunization stress-related response (ISRR) (n=5, 16.67%), injected
411 site pain (n=3, 10%), maculopapular rash (n=2, 6.67%), and others were
412 described in Supplementary Table 2. Only 7 participants had severe AE
413 included anaphylaxis (n=5, 16.67%), stroke (n=1, 3.33%) and
414 central venous sinus thrombosis (n=1, 3.33%). Consequently, all participants in
415 group 1a alter to receive the viral vector in the second dose due to the AE from
416 the first vaccination (Table 2).

417 The group 1b were 125 participants from the MOPH vaccination center who
418 received the I/V regimen based on the recommended vaccine schedule. This
419 group has lower rates of reactogenicity from CoronaVac, the most common
420 systemic reactions were feeling feverish (n=8, 6.4%), drowsiness (n=5, 4%),
421 headache (n=2, 1.6%), and local AE such as injection site pain
422 (n=1, 0.8%) (Table3).

423

424 **Reactogenicity to second dose ChAdOx1 nCoV-19.**

425 After ChAdOx1 nCoV-19 as second vaccine, in total 155 participants, the most
426 common systemic AEs were feeling feverish (n=104,67.10%), headache (n=51,32.9%),
427 myalgia (n=40,25.81%), and malaise and drowsiness (n=30,19.35%). The most

428 common local responses such as injection site pain (n=54,35.06%) and other
429 were described in Supplementary(Table4).
430

431 **Discussion**

432 The higher level of antibody response and neutralizing activity at 4 weeks
433 against the Delta variant following the I/V schedule is encouraging for the
434 national vaccine program implementation.

435 In our study, heterologous I/V vaccination with a mean 3.5-week interval
436 presents antibody levels at 4 wks that are significantly higher than V/V, I/I, and
437 natural infection 2021. This result could be explained from additional support
438 from study[14], the author demonstrated in mice that the first dose of inactivated
439 viral vaccine followed by adenovirus vectors vaccine induced a significantly
440 prominent T-cell response than two doses of inactivated vaccines. These might
441 help B cell greater differentiation into plasma B cell that could provide
442 higher antibody response to specific antigen more two doses of
443 inactivated vaccines[15] .

444 In addition, antibody levels of the I/I schedule at 4 wks were lower than
445 natural infection 2021.This agreement with a prior study that
446 S1-RBD-binding IgG titer of natural infection 2021 was higher than
447 homologous CoronaVac vaccination[8].

448 Additionally, the I/V schedule provided a higher Nab level at
449 2wks against Alpha variants than the Beta variant. This is compatible with a
450 previous study utilizing a pseudovirus neutralization assay, serum from
451 CoronaVac vaccinees collected 14 days following the second dose of the vaccine
452 presented higher Beta resistance to neutralization than Alpha[16] . Moreover, this Nab
453 level at 2wks against all VOCs decreased significantly compared to WT
454 correlate with study[8].
455 The Nab is highest to wild type variant, then to Alpha variant followed
456 by delta variant, and the least Nab to Beta variant. This is consistent with a
457 study that analyzed neutralization capacities by protein-based 206 ACE2 RBD
458 competition assay was highest in wild-type, followed by alpha, delta, and Beta,
459 respectively[17].
460 Besides, participants in the I/V schedule resulted in high $PRNT_{50}$ and
461 $PVNT_{50}$ titers against to delta variant. Immune protection against SARS-CoV-2
462 infection symptoms are highly correlated with levels of neutralising
463 antibodies[18].The AstraZeneca vaccines were shown to be 60% effective against
464 the Delta variant after two doses[19].
465 This evidence provides supporting information for this I/V vaccination
466 schedule in Thailand. Availability of immunogenicity data from the I/V
467 vaccination schedule is vital for consideration of the national vaccination
468 program to consider the best vaccine schedule that could stimulate the higher
469 level of immunogenicity. Since the immunogenicity study may not be feasible

470 for every country, lower- and middle-income countries where inactivated viral
471 vaccine and viral vector vaccine is available may use this evidence to support
472 their decision to use alternative vaccination schedules. While multiple
473 inactivated viral vaccines and viral vector vaccines are available, not all
474 combinations of vaccine schedules produce satisfactory immunogenicity
475 response, the early analysis in Thailand suggested that viral vector followed by
476 inactivated viral vaccine-induced unsatisfactory immunogenicity[20]. While the
477 correlation of protection for COVID19 vaccine has not been officially declared
478 by World Health Organization, neutralizing activity to SARS-CoV-2 variants is
479 likely related to the effectiveness of vaccination schedule [21]. Each country can
480 measure the immunogenicity of these vaccination schedules in the target
481 population and utilized this information to guide the vaccination schedules at
482 the national level. In countries with CoronaVac and ChAdOx1 nCoV19 are
483 available like Thailand, using this heterologous vaccination schedule is likely to
484 enable the highest level of immunogenicity to Delta variants from these two
485 vaccines.

486 An individual with a low level of immune response after COVID
487 vaccination with this I/V schedule was diagnosed with HIV infection with a low
488 level of CD4. Two sources of information are used to make a prediction and
489 identify the possible problem. Infection with HIV, which causes immunological
490 damage to B-cell compartments and antibody production, might be substantially
491 reduced humoral response to antigens and insufficient response of persons

492 living with HIV to alternative vaccination, especially in those with low CD4 T-
493 cell counts22.While immunogenicity is the proxy to the higher effectiveness, it
494 is prudent to evaluate the safety and effectiveness of novel vaccine schedules
495 after their introduction21. The introduction of the heterologous schedule of
496 ChAdOx1 nCoV-19 followed by mRNA vaccination was evaluated for this
497 vaccination schedule effectiveness (VE) in 100,000 fully vaccinated individuals,
498 the real world VE of this vaccination schedule was at 88% (95% CI,83-92)[23] .
499 The large-scale evaluation of safety and effectiveness for the I/V schedule is
500 still carried out in Thailand, the results of VE study should come out in the next
501 month.

502 The adverse reactions to vaccination in this study were described
503 separately from two groups(1a,1b) of samples. Group 1a reported a higher rate
504 of AEs from the first vaccination with the inactivated viral vaccine because this
505 group received the viral vector due to the AEs from the first vaccination, the
506 AEs rates from this group are not representative of AEs from the general
507 population.Group 2b was retrieved from the general population that went to the
508 vaccination center, the AEs from group 1b can be used as representative of
509 general populations. The common AEs for the first vaccination with an
510 inactivated viral vector was feeling feverish (n =8,6.4 %). According to our
511 initial findings, the AEs after the second dose of ChAdOx1 nCoV-19 in the I/V
512 schedule were well tolerated and generally safe. The adverse event

513 profile reported here is comparable to previously reported adverse events
514 following vaccination with ChAdOx1 nCoV-19[24]. Most participants had mild or
515 moderate adverse effects and no report of serious AEs.The severity of local and
516 systemic AEs of I/V schedule after the second dose of ChAdOx1 nCoV-19 in 7
517 days was mild to moderate corresponded to the reported AEs in phase II and
518 phase III study of ChAdOx1 nCoV-19 (UK, Brazil, South Africa)[25] . The rate of
519 systemic AEs, such as fever, recorded after the second dosage of ChAdOx1
520 nCoV-19 was higher (67.1%) than the earlier study (51%)[26]. However, Both
521 systemic AEs (such as headache, malaise, myalgia) and local AE (such as
522 injection site pain) were lower rates than this study[26]. This higher level of
523 immunogenicity and the acceptable level of adverse reactions profile of
524 this I/V vaccination schedule, this vaccination schedule is likely a better
525 solution for countries that had access to both Inactivated whole virus vaccine
526 and viral vector vaccine-like Thailand. The questions that remained to be
527 answered are the duration of immunogenicity which may need following up
528 study at 3 months, 6 months, 9 months, and 1 year. The decreasing levels of
529 antibody level at 2 weeks to 4 weeks suggested that immunogenicity level may
530 last between 3 to 6 months and the temporal relationship of effectiveness should
531 be monitored carefully by the national vaccination program. The third dose is
532 likely necessary for boosting immunogenicity after the I/V vaccine schedule and

533 the types and timing of vaccine should be determined as the follow-up study
534 from this cohort of vaccine recipients for providing a further recommendation.
535 There are several limitations to our research. First, our study did not
536 collect comparison data on immunity levels at baseline before the study and
537 after the first vaccine dose, hence, we could not exclude the effect of the
538 previous infection on immunogenicity. However, the COVID-19 infection rate
539 in Thailand was low before July 2021, there is a small possibility to include
540 previously infected COVID-19 cases but these individuals should not affect the
541 immunogenicity results in this study due to the immunity induced by infection
542 were much higher in previously infected individuals compared with single-dose
543 vaccination. A larger sample size is needed to detect uncommon adverse events
544 such as vaccine-induced thrombotic thrombocytopenia and further studies
545 should be done at the time of implementation of this vaccine schedule in the
546 national vaccine program. Moreover, the $PRNT_{50}$ and $PVNT_{50}$ were assessed
547 only in I/V regimen, limiting the comparability of the I/V regimen with other
548 vaccine schedules, also the limited time for this study resulted in a smaller
549 sample size that had neutralizing activities, however, the high level of
550 neutralizing antibody suggested that the number of sample size is sufficient for
551 the conclusion that I/V schedule is better than I/I schedule and comparable to
552 V/V schedule.
553 Finally, our research offers crucial real-world proof of the safety and
554 immunogenicity of heterologous CoronaVac- ChAdOx1 nCoV-19

immunization. The I/V vaccination is a mixed regimen that induced higher immunogenicity with a shorter duration to peak immunogenicity compared to the I/I schedule. In a situation where the viral vector vaccine is inadequate, we should consider this vaccine schedule for responding to Delta Variants. We propose that this initial assessment encourage future research of heterologous prime-boost vaccination regimens for COVID-19.

Ethics Statement

The ethical approval of this study was approved by the ethical committee of the Department of Medical Sciences with approval number; MOPH 0625/EC060

Conflicts of interest

All authors declare no conflict of interest.

Funding

Department of Medical Sciences provided funding for this project. Studies, data collection, analysis, and interpretation, as well as manuscript preparation and the determination to submit the paper for publication, were all independent of funding sources.

Acknowledgments

We would like to express our gratitude to the whole COVID-19 research team including all of the study participants. We thank Dr. Mark Simmerman for his critical data and recommendations.

576

577

578

579

580 References

581 1. Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
582 *https://doi.org/10.1056/NEJMc2112423* (2021) doi:10.1056/NEJMC2112423.

583 2. Bernal, J. L. *et al.* Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.
584 *medRxiv* 2021.05.22.21257658 (2021) doi:10.1101/2021.05.22.21257658.

585 3. Lu, S. Heterologous Prime-Boost Vaccination. *Current opinion in immunology* **21**, 346
586 (2009).

587 4. Logunov, D. Y. *et al.* Safety and immunogenicity of an rAd26 and rAd5 vector-based
588 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-
589 randomised phase 1/2 studies from Russia. *The Lancet* **396**, 887–897 (2020).

590 5. Abhishek Anand, Justin Sandefur, Arvind Subramanian write: Why we need to count
591 the Covid dead. https://indianexpress.com/article/opinion/columns/india-covid-deaths-
592 second-wave-7412619/.

593 6. Dyer, O. Covid-19: Indonesia becomes Asia's new pandemic epicentre as delta variant
594 spreads. *BMJ* **374**, n1815 (2021).

595 7. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
596 coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* **395**, 507–
597 513 (2020).

598 8. Vacharathit, V. *et al.* SARS-CoV-2 variants of concern exhibit reduced sensitivity to
599 live-virus neutralization in sera from CoronaVac vaccinees and naturally infected
600 COVID-19 patients. *medRxiv* 2021.07.10.21260232 (2021)
601 doi:10.1101/2021.07.10.21260232.

602 9. Yorsaeng, R. *et al.* Immune response elicited from heterologous SARS-CoV-2
603 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). *medRxiv*
604 2021.09.01.21262955 (2021) doi:10.1101/2021.09.01.21262955.

605 10. di Genova, C. *et al.* Production, titration, neutralisation and storage of SARS-CoV-2
606 lentiviral pseudotypes (preprint). *Methods and Protocols preprint server* (2020)
607 doi:10.6084/M9.FIGSHARE.13502580.V2.

608 11. R: The R Project for Statistical Computing. https://www.r-project.org/.

609 12. RStudio - RStudio. https://www.rstudio.com/products/rstudio/.

610 13. Alboukadel Kassambara. rstatix: Pipe-Friendly Framework for Basic Statistical Tests.
611 R package version 0.7.0. https://cran.r-project.org/package=rstatix (2021).

612 14. Zhang, J. *et al.* Boosting with heterologous vaccines effectively improves protective
613 immune responses of the inactivated SARS-CoV-2 vaccine.
614 *https://doi.org/10.1080/22221751.2021.1957401* 1–28 (2021)
615 doi:10.1080/22221751.2021.1957401.

616 15. Takemori, T., Tarlinton, D., Hiepe, F. & Andreas, R. B Cell Memory and Plasma Cell
617 Development. *Molecular Biology of B Cells: Second Edition* 227–249 (2015)
618 doi:10.1016/B978-0-12-397933-9.00014-X.

619 16. GL, W. *et al.* Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
620 *The New England journal of medicine* **384**, 2354–2356 (2021).

621 17. Junker, D. *et al.* Reduced serum neutralization capacity against SARS-CoV-2 variants
622 in a multiplex ACE2 RBD competition assay. *medRxiv* 2021.08.20.21262328 (2021)
623 doi:10.1101/2021.08.20.21262328.

624 18. Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune
625 protection from symptomatic SARS-CoV-2 infection. *Nature Medicine 2021 27:7* **27**,
626 1205–1211 (2021).

627 19. Bernal, J. L. *et al.* Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.
628 *medRxiv* 2021.05.22.21257658 (2021) doi:10.1101/2021.05.22.21257658.

629 20. Wanlapakorn, N. *et al.* Immunogenicity of heterologous prime/booster-inactivated and
630 adenoviral-vectored COVID-19 vaccine: real-world data. (2021)
631 doi:10.21203/RS.3.RS-785693/V2.

632 21. Earle, K. A. *et al.* Evidence for antibody as a protective correlate for COVID-19
633 vaccines. *medRxiv* 2021.03.17.20200246 (2021) doi:10.1101/2021.03.17.20200246.

634 22. Ambrosioni, J. *et al.* Overview of SARS-CoV-2 infection in adults living with HIV.
635 *The Lancet HIV* **8**, e294–e305 (2021).

636 23. Gram, M. A. *et al.* Vaccine effectiveness when combining the ChAdOx1 vaccine as
637 the first dose with an mRNA COVID-19 vaccine as the second dose. *medRxiv*
638 2021.07.26.21261130 (2021) doi:10.1101/2021.07.26.21261130.

639 24. Folegatti, P. M. *et al.* Safety and immunogenicity of a candidate Middle East
640 respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-
641 label, non-randomised, uncontrolled, phase 1 trial. *The Lancet Infectious Diseases* **20**,
642 816–826 (2020).

643 25. Ramasamy, M. N. *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine
644 administered in a prime-boost regimen in young and old adults (COV002): a single-
645 blind, randomised, controlled, phase 2/3 trial. *The Lancet* **396**, 1979–1993 (2020).

646 26. Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine
647 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised
648 controlled trial. *The Lancet* **396**, 467–478 (2020).

649